DEPARTMENT OF HEALTH AND HUMAN SERVICES

Indian Health Service

Tribal Self-Governance Program Planning Cooperative Agreement; Correction

ACTION: Notice; correction.


FOR FURTHER INFORMATION CONTACT: Matt Johnson, Office of Tribal Self-Governance, Indian Health Service, 801 Thompson Avenue, Suite 240, Rockville, MD 20852. Telephone (301) 443–1982. (This is not a toll-free number.)

Correction

In the Federal Register of March 31, 2008, in FR Doc. E8–6406, on page 16874, in the second column, correct the Funding Announcement Number to read: HHS–2008–IHS–TSGP–0002; page 16875, in the first column, Under III. Eligibility Information, 3. Other Requirements, Letter B, change Friday April 25, 2008 to Tuesday, May 6, 2008, and in the following sentence change April 25, 2008 to May 6, 2008; and on page 16878, in the first column, first paragraph, change matthew.johnson@ihs.gov to matthew.johnson@ihs.gov.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Indian Health Service

Tribal Self-Governance Program Negotiation Cooperative Agreement; Correction

ACTION: Notice; correction.


FOR FURTHER INFORMATION CONTACT: Matthew Johnson, Acting Director, Indian Health Service, 801 Thompson Avenue, Suite 240, Rockville, MD 20852. Telephone (301) 443–1982. (This is not a toll-free number.)

Correction

In the Federal Register of March 31, 2008, in FR Doc. E8–6428, on page 16871, in the second column, under III. Eligibility Information, 3. Other Requirements, Letter C, change Friday April 25, 2008 to Tuesday, May 6, 2008, and in the following sentence change April 25, 2008 to May 6, 2008; and on page 16874, in the second column, first paragraph, change matthew.johnson@ihs.gov to matthew.johnson@ihs.gov.

Dated: April 18, 2008.

Robert G. McSwain,
Acting Director, Indian Health Service.

[FR Doc. E8–9246 Filed 4–28–08; 8:45 am]

BILLING CODE 4155–16–M

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Assay for Identification of Influenza-Neutralizing Antibodies

Description of Technology: Development of effective vaccines against influenza, especially pandemic or avian, is a subject of intense current research efforts. The efficacy of these vaccines has historically been assessed using hemagglutination inhibition (HAI) assays. However, HAI assays are limited in their utility by lack of standardization amongst laboratories. The NIH is pleased to offer the subject technology, a system to quantitate virus neutralization and entry. This system utilizes pseudotyped lentiviral vectors that mimic properties of the influenza virus. Experimental use of this system has shown an increase in sensitivity more than ten times that achieved with HAI assays. This standardized system can allow influenza vaccine candidates to be evaluated and compared, which can be a critical step in identifying the best product forward.

Applications: Quick, high-throughput, sensitive and quantitative measure of neutralizing antibodies for vaccine development; Identification of therapeutic monoclonal antibodies.

Advantages: Standardized assay, unlike currently utilized assays; Generation of comparable data for various vaccine candidates.

Development Status: Comparative data against current standard available. Inventors: Gary Nabel and Zhi-yong Yang (NIAID).


Licensing Status: Available for exclusive or non-exclusive licensing. Licensing Contact: Susan Ano, Ph.D.; 301–435–5515; anos@mail.nih.gov.

Influenza Vaccines, Therapeutics, and Monoclonal Antibodies

Description of Technology: Concerns about a potential influenza pandemic and its prevention are a regular part of health news, with bird (avian) influenza (prominently including H5N1 strains) being a major concern. Vaccination is one of the most effective ways to